Trastuzumab deruxtecan (DS-8201a) is a novel HER2-targeted antibody-drug conjugate with a humanised anti-HER2 antibody, cleavable peptide-based linker, and potent topoisomerase I inhibitor payload. A phase 1, non-randomised, open-label, multiple-dose study was done to assess the safety, ...
第一三共的Enhertu(fam-trastuzumab deruxtecan-nxki,T-DXD,DS-8201a)是一种新一代ADC(抗体偶联)药物,通过一种4肽链接子将靶向HER2的人源化单克隆抗体曲妥珠单抗(trastuzumab)与一种拓扑异构酶1抑制剂exatecan衍生物链接在一起,可靶向...
Trastuzumabderuxtecan (T-Dxd, or DS-8201a) is a second-generation ADC developed to overcome the GC-specific challenges forHER2targeted therapy. It is composed oftrastuzumab, arestriction endonucleaselinker, and a newDNA topoisomerase I inhibitor(Drutecan). Trastuzumab modulates the expression of top...
Synonyms: DS-8201 Catalog No.E0200Purity:99.86% Trastuzumab deruxtecan (DS-8201a, T-DXd) is anantibody-drug conjugate (ADC)composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody and a cytotoxic topoisomerase I inhibitor. Trastuzumab deruxtecan shows durable antitumor activi...
当然,德曲妥珠单抗(T-DXd、Enhertu®、DS-8201、Trastuzumab deruxtecan)作为首款具有不限癌种适应症的ADC药物,可同时杀伤目标肿瘤细胞和邻近的肿瘤细胞,具有不俗的广谱抗癌疗效,除了治疗胃癌外,还获批用于治疗以下癌种: 01、转移性或不可切除的HER2-low(IHC2+/ISH-或IHC1+)乳腺癌,且既往接受过化疗,或在化...
直至新型ADC药物 fam-trastuzumab deruxtecan-nxki(Enhertu,此前称为T-DXd或DS-8201a)的问世,打破了只有HER2阳性乳腺癌才能从抗HER2靶向治疗中获益的传统认知,HER2低表达的精准治疗时代来临。 ▲ADC药物Enhertu的作用机制:Enhertu与肿瘤细胞表面的HER2蛋白(浅绿色)结合,然后通过细胞内吞作用进入细胞内,随后药物的...
Trastuzumab deruxtecan品牌:MedChemExpress (MCE)CAS:1826843-81-5货号:HY-138298ASynonyms:DS-8201; DS-8201a存储条件:-80°C,避光保存运输条件:使用干冰运输。产品活性:Trastuzumab deruxtecan (T-DXd; DS-8201a) 是一种抗人表皮生长因子受体 2 (HER2) 抗体-活性分子偶联物 (ADC)。Trastuzumab deruxtecan...
直至新型ADC药物 fam-trastuzumab deruxtecan-nxki(Enhertu,此前称为T-DXd或DS-8201a)的问世,打破了只有HER2阳性乳腺癌才能从抗HER2靶向治疗中获益的传统认知,HER2低表达的精准治疗时代来临。 ▲ADC药物Enhertu的作用机制:Enhertu与肿瘤细胞表面的HER2蛋白(浅绿色)结合,然后通过细胞内吞作用进入细胞内,随后药物的...
Trastuzumab deruxtecan (T-DXd; DS-8201a) 是一种抗人表皮生长因子受体 2 (HER2) 抗体-活性分子偶联物 | MedChemExpress (MCE)-抑制剂,化合物库-MedChemExpress(MCE中国)
DS-8201(又称Enhertu®、T-DXd、德曲妥珠单抗、Trastuzumab deruxtecan)是一种靶向人表皮生长因子2(HER2)的新型抗体药物偶联物(ADC),由新型有效的喜树碱类似物拓扑异构酶I抑制剂(DXd)、新开发的酶切割连接子、人源化的抗HER2抗体三部分组成,可同时杀伤目标肿瘤细胞及邻近肿瘤细胞。